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Abstract. Modification of naturally occurring nucleosides is an important area in the search for new 
agents with therapeutic potential. In this study, nucleoside molecules, that is, cytidine analogs bearing 
ribose moieties were successfully synthesized to obtain 5´-O-acyl cytidine (2), which in turn was 
converted into 2 ,́3´-di-O-acyl cytidine (3–7) through direct acylation. Similarly, several cytidine 
analogs (8–15) were formed using the aforementioned technique. Physicochemical properties and 
spectroscopic methods were used to characterize the newly synthesized cytidine analogs. X-ray 
powder diffraction was employed for quantitatively identifying crystalline compounds. Hence, these 
synthesized derivatives can be used as potential antimicrobial agents and promising drug candidates.
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Аннотация. Модификация природных нуклеозидов – важная область в поиске новых агентов 
с терапевтическим потенциалом. В этом исследовании нуклеозидные молекулы, являющиеся 
аналогами цитидина, с рибозными фрагментами были успешно использованы для синтеза 
5-0-ацил цитидина (2), который в свою очередь был превращен в 2,3-ди-0-ацил цитидин 
(3-7) путем прямого ацилирования. Точно так же, с использованием вышеописанного метода, 
получено несколько аналогов цитидина (8-15). Синтезированные новые аналоги цитидина 
были охарактеризованы физико-химическими методами. Для количественной идентификации 
кристаллических соединений применили метод порошковой рентгеновской дифракции. Эти 
синтезированные производные могут быть использованы как потенциальные антимикробные 
агенты и перспективные лекарственные препараты.
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Introduction
Nucleosides and their analogues are of enormous importance. They are an established class 
of clinically useful medicinal agents, possessing antiviral and anticancer activity [1-3]. A number 
of different types of nucleosides have been synthesized from time to time which are reported to be 
biologically active, for example, ribavirin or virazole is an important such nucleoside. It has been 
reported as one of the most powerful synthetic antiviral agent’s active against DNA viruses [4]. 
Virazole has been approved by the FDA for the treatment of viral infections [5]. The 5-azacytidine 
has been shown to possess promising activity against adult non-lymphocytic leukemia. It can either 
be synthesized chemically or produced microbiologically. It mainly affects the synthesis and function 
of DNA [6]. 2 ,́3´-Dideoxycytidine also been reported to inhibit HIV and its clinical trials have been 
successfully carried out at NIH in AIDS patients [7]. Structural modifications of nucleosides have 
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given rise to widely used drugs such as zidovudine [8] and acyclovir [9], which demonstrates that this 
strategy offers interesting opportunities to synthesize new therapeutically useful compounds.
Cytidine (Fig. 1) is a nucleoside that consists of a sugar part, ribose, which is linked to the 
pyrimidine base cytosine via a β-glycosidic bond. Cytidine is a component of RNA and a precursor for 
uridine. When RNA-rich food is consumed, RNA is broken down into ribosyl pyrimidines (cytidine 
and uridine) and its basic elements are released for absorption from intestine [10]. RNA-rich foods 
are considered good cytidine sources. The supplementation of dietary cytidine (5´)-diphosphocholine 
protects against the development of memory deficits [11].
Modifications in the sugar moiety of nucleosides have resulted in various effective therapeutic 
applications. In the last few years, many researchers have investigated the selective acylation of the 
hydroxyl groups of the ribose moieties of nucleosides and nucleotides by using various methods 
[12, 13]. Different methods for nucleoside acylation have been successfully developed and employed 
[14, 15]. Among those, a direct method is most encouraging for nucleoside acylation [16]. 
Encouraged by the literature [17, 18] and our findings [19-21], we synthesized some selectively 
acylated analogs of cytidine (schemes 1–4) containing various substituents in a single molecular 
framework and X-ray diffraction studies on them for the first time.
Experimental
Materials and methods
Thin layer chromatography (TLC) was performed on Kieselgel GF254, and visualization was 
achieved by spraying plates with 1% H2SO4 followed by heating the plates at 150–200 °C until coloration 
occurred. Melting points (m.p.) were determined using an electrothermal melting point apparatus and 
were uncorrected. Evaporation was performed using a Büchi rotary evaporator under diminished 
pressure. Analytical grade solvents were employed and purified using standard procedures. Infrared 
(IR) spectral analyses were conducted using a Fourier transform IR (FTIR) spectrophotometer (IR 
Prestige-21, Shimadzu, Japan) within 200–4000 cm−1 at the Department of Chemistry, University 
of Chittagong, Bangladesh. The mass spectra of the synthesized compounds were recorded through 
liquid chromatography electrospray ionization-tandem mass spectrometry in the positive ionization 
mode (LC/ESI(+)-MS/MS) by using a system comprising a JASSO LC (JASCO, Japan). A Brucker 
advance DPX 400 MHz with tetramethylsilane as an internal standard was used to record 1H-NMR 
Fig. 1. Structure of cytidine
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spectra in CDCl3 (δ in ppm) at WMSRC, JU, Bangladesh. XRD patterns were obtained using an 
XRD-53 analyzer, Rigaku, Japan diffractometer, with a back monochromator and Cu target and Kα 
(λ = 1.5406 nm) in 2θ = 2°–70° at CARS, Dhaka University, Bangladesh. Column chromatography was 
performed with silica gel G60. CHCl3/CH3OH was employed as the solvent system for TLC analyses 
was in different proportions. All reagents used were commercially available (Aldrich) and used without 
further purification unless otherwise specified. 
Synthesis
Over past several years, our laboratory has been synthesizing nucleoside derivatives containing 
various acyl groups to explore their antimicrobial properties [30, 31]. 
In dry DMF (N,N-dimethylformamide) (3 ml), a cytidine (1) (70 mg, 0.287 mmol) solution was 
cooled to −5 °C when decanoyl chloride (65 mg, 1.1 molar eq.) was added. The solution was stirred at 
this temperature for 5 to 6 h and then was allowed to stand at room temperature overnight. Reaction 
progress was monitored through TLC, which indicated the complete conversion of the starting material 
into a single product. A few pieces of ice were added to the flask to stop the reaction. Subsequently, 
the solvent was evaporated using a high pressure vacuum evaporator, and the resulted product was 
passed through silica gel column chromatography and eluted with (1:24), which provided the decanoyl 
derivative (2) (92 mg). The recrystallization of (CHCl3–C6H14) led to the formation of the title derivative 
(2) as needles. The compound was sufficiently pure for subsequent use without further treatment and 
identification.
5´-O-Decanoylcytidine (2): Yield 83.8% as crystalline solid, M.P. 85–87 °C (CHCl3–C6H14), 
Rf = 0.51 (CHCl3/CH3OH = 24/1, v/v). FTIR: νmax 1731, 1714 (-CO), 3550 (-NH), 3420 cm-1 (-OH). 
1H -NMR (400 MHz, CDCl3): δH 9.02 (1H, s, -NH), 7.44 (1H, d, J = 7.8 Hz, H-6), 6.56 (1H, d, J = 3.0 Hz, 
H-1́ ), 6.49 (1H, s, 2´-OH), 6.01 (1H, dd, J = 2.4 and 12.3 Hz, H-5 á), 5.56 (1H, dd, J = 2.4 and 12.3 Hz, 
H-5´b), 5.45 (1H, s, 3´-OH), 4.85 (1H, dd, J = 2.4 and 5.6 Hz, H-4´), 4.60 (2H, s, -NH2), 4.45 (1H, d, 
J = 3.2 Hz, H-2´), 4.31 (1H, dd, J = 3.6 and 5.8 Hz, H-3´), 3.80 (1H, d, J = 7.2 Hz, H-5), 2.38 {2H, 
m, CH3(CH2)7CH2CO-}, 1.59 {2H, m, CH3(CH2)6CH2CH2CO-}, 1.32 {12H, m, CH3(CH2)6(CH2)2CO-}, 
0.85 {3H, m, CH3(CH2)8CO-}. MS [M+1]+ 398.10.
Anal Calcd. for C19H31N3O6 : % C, 72.54, H, 7.81; found: % C, 72.53, H, 7.82. 
General procedure for the direct 2′,3′-di-O-acylation  
of 5´-O-decanoylcytidine (2) derivatives (3–7) 
In DMF (3 ml), octanoyl chloride (0.185 ml, 4 molar eq.) was added to a cooled (0 °C) and stirred 
solution of the decanoyl derivative (2) (110 mg, 0.276 mmol). The mixture was stirred at 0 °C for 
8 h and then allowed to stand overnight at room temperature. TLC analyses showed the complete 
conversion of reactants into a single product. A few pieces of ice were added to the reaction flask to 
eliminate the excess reagent, and the reaction mixture was evaporated using the high-pressure vacuum 
evaporator to remove the solvent. The percolation of the resulting product achieved by passing through 
a silica gel column with the CHCl3–CH3OH eluant led to the formation of the octanoyl derivative (3) 
(163 mg) as a crystalline solid. 
A similar reaction and purification procedure was employed to prepare compounds (4), (5), (6), 
and (7). 
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5´-O-Decanoyl-2 ,́3´-di-O-octanoylcytidine (3): Yield 77.6% as a white crystalline solid, M.P. 
89–91 °C (CHCl3–C6H14), Rf = 0.51 (CHCl3/CH3OH = 24/1, v/v). FTIR: νmax 1729, 1716 (-CO), 3470 cm-1 
(-NH). 1H-NMR (400 MHz, CDCl3): δH 9.18 (1H, s, -NH), 7.27 (1H, d, J = 7.8 Hz, H-6), 6.54 (1H, d, 
J = 3.2 Hz, H-1́ ), 5.45 (1H, m, H-2´), 4.82 (1H, dd, J = 3.5 and 5.6 Hz, H-3´), 4.67 (1H, dd, J = 2.4 and 
12.2 Hz, H-5 á), 4.58 (2H, s, -NH2), 4.55 (1H, dd, J = 2.4 and 12.2 Hz, H-5´b), 4.38 (1H, dd, J = 2.4 
and 5.5 Hz, H-4´), 3.70 (1H, d, J = 7.2 Hz, H-5), 2.37 {4H, m, 2×CH3(CH2)5CH2CO-}, 1.64 {4H, m, 
2×CH3(CH2)4CH2CH2CO-}, 1.29 {16H, m, 2×CH3(CH2)4(CH2)2CO-}, 0.89 {6H, m, 2×CH3(CH2)6CO-}. 
MS [M+1]+ 650.09.
Anal Calcd. for C35H59O8N3: % C, 64.71, H, 9.09; % found: C, 64.73, H, 9.06. 
5´-O-Decanoyl-2 ,́3´-di-O-palmitoylcytidine (4): Yield 91.2% as a white crystalline solid, M.P. 
78–79 °C (CHCl3–C6H14), Rf = 0.54 (CHCl3/CH3OH = 24/1, v/v). FTIR: νmax 1696 (-CO), 3500 cm-1 
(-NH). 1H-NMR (400 MHz, CDCl3): δH 9.10 (1H, s, -NH), 7.29 (1H, d, J = 7.7 Hz, H-6), 6.52 (1H, 
d, J = 3.2 Hz, H-1́ ), 5.48 (1H, m, H-2´), 4.86 (1H, dd, J = 3.5 and 5.6 Hz, H-3´), 4.67 (1H, dd, J = 2.4 
and 12.1 Hz, H-5 á), 4.58 (2H, s, -NH2), 4.56 (1H, dd, J = 2.4 and 12.1 Hz, H-5´b), 4.41 (1H, dd, 
J = 2.4 and 5.5 Hz, H-4´), 3.81 (1H, m, H-5), 2.36 {4H, m, 2×CH3(CH2)13CH2CO-}, 1.27 {52H, m, 
2×CH3(CH2)13CH2CO-}, 0.91 {6H, m, 2×CH3(CH2)14CO-}. MS [M+1]+ 874.30. 
Anal Calcd. for C51H91O8N3: % C, 70.10, H, 10.42; found: % C, 70.13, H, 10.40. 
5´-O-Decanoyl-2 ,́3´-di-O-stearoylcytidine (5): Yield 85.3% as crystalline solid, M.P. 95–
97 °C (CHCl3–C6H14), Rf = 0.50 (CHCl3/CH3OH = 23/1, v/v). FTIR: νmax 1709 (-CO), 3490 cm-1 
(-NH). 1H-NMR (400 MHz, CDCl3): δH 9.08 (1H, s, -NH), 7.28 (1H, d, J = 7.7 Hz, H-6), 6.68 (1H, 
d, J = 3.2 Hz, H-1́ ), 6.48 (1H, m, H-2´), 6.21 (1H, dd, J = 3.5 and 5.6 Hz, H-3´), 6.07 (1H, dd, 
J = 2.4 and 12.1 Hz, H-5 á), 5.51 (1H, dd, J = 2.4 and 12.1 Hz, H-5´b), 5.21 (1H, dd, J = 2.4 and 
5.5 Hz, H-4´), 4.88 (2H, s, -NH2), 4.11 (1H, m, H-5), 2.36 {4H, m, 2×CH3(CH2)15CH2CO-}, 1.65 
{4H, m, 2×CH3(CH2)14CH2CH2CO-}, 1.27 {56H, m, 2×CH3(CH2)14CH2CH2CO-}, 0.90 {6H, m, 
2×CH3(CH2)16CO-}. MS [M+1]+ 930.23. 
Anal Calcd. for C55H99O8N3: % C, 71.0, H, 10.60; % found: C, 71.03, H, 10.63. 
5´-O-Decanoyl-2 ,́3´-di-O-(triphenylmethyl)cytidine (6): Yield 84.3% as a white crystalline 
solid, M.P. 102–104 °C (CHCl3–C6H14), Rf = 0.52 (CHCl3/CH3OH = 22/1, v/v). FTIR: νmax 1686 (-CO), 
3496 cm-1 (-NH). 1H-NMR (400 MHz, CDCl3): δH 9.02 (1H, s, -NH), 7.58 (12H, m, 2×Ar-H), 7.36 (18H, 
m, 2×Ar-H), 7.22 (1H, d, J = 7.6 Hz, H-6), 6.61 (1H, d, J = 3.2 Hz, H-1́ ), 5.47 (1H, d, J = 3.2 Hz, H-2´), 
4.88 (1H, dd, J = 3.6 and 5.6 Hz, H-3´), 4.68 (1H, dd, J = 2.3 and 12.1 Hz, H-5 á), 4.60 (2H, s, -NH2), 
4.57 (1H, dd, J = 2.4 and 12.1 Hz, H-5´b), 4.49 (1H, dd, J = 2.4 and 5.5 Hz, H-4´), 3.92 (1H, m, H-5). 
MS [M+1]+ 882.12. 
Anal Calcd. for C57H59O6N3: % C, 77.60, H, 6.71; % found: C, 77.62, H, 6.73. 
5´-O-Decanoyl-2 ,́3´-(4-tert-butylbenzoyl)cytidine (7): Yield 90.4% as crystalline solid, M.P. 
109–111 °C (CHCl3–C6H14), Rf = 0.52 (CHCl3/CH3OH = 24/1, v/v). FTIR: νmax 1712 (-CO), 3501 cm-1 
(-NH). 1H-NMR (400 MHz, CDCl3): δH 9.03 (1H, s, -NH), 8.06 (4H, m, 2×Ar-H), 7.51 (4H, m, 2×Ar-H), 
7.28 (1H, d, J = 7.7 Hz, H-6), 6.68 (1H, d, J = 3.2 Hz, H-1́ ), 5.57 (1H, m, H-2´), 4.96 (1H, dd, J = 3.5 
and 5.6 Hz, H-3´), 4.66 (1H, dd, J = 2.4 and 12.1 Hz, H-5 á), 4.54 (2H, s, -NH2), 4.52 (1H, dd, J = 2.4 
and 12.1 Hz, H-5´b), 4.25 (1H, dd, J = 2.4 and 5.5 Hz, H-4´), 4.01 (1H, m, H-5), 1.33, 1.28 {18H, 2×s, 
2×(CH3)3C-}. MS [M+1]+ 718.11. 
Anal Calcd. for C41H55O8N3: % C, 68.60, H, 7.60; % found: C, 68.63, H, 7.58. 
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In dry DMF (3 ml), a cytidine (1) (70 mg, 0.287 mmol) solution was cooled to −5 °C and treated 
with 1.1 molar equivalent of triphenylmethyl chloride (85 mg) with continuous stirring at the same 
temperature for 5 to 6 h. Stirring was continued overnight at room temperature. Reaction progress 
was monitored through TLC. A few pieces of ice were added to the flask to terminate the reaction. 
Subsequently, the solvent was evaporated using the high-pressure vacuum evaporator. The resulting 
syrupy mass was purified through silica gel column chromatography (with CHCl3–CH3OH, 1:24 
eluant) to acquire the title compound (8, 107 mg) as a crystalline solid.
5´-O-(Triphenylmethyl)cytidine (8): Yield 81.2% as a white crystalline solid, M.P. 75–77 °C) 
(CHCl3–C6H14), Rf = 0.50 (CHCl3/CH3OH = 24/1, v/v). FTIR: νmax 1701 (-CO), 3547 (-NH), 3416-3468 
(br) cm-1 (-OH). 1H -NMR (400 MHz, CDCl3): δH 9.01 (1H, s, -NH), 7.35 (6H, m, Ar-H), 7.30 (9H, m, 
Ar-H), 7.23 (1H, d, J = 7.8 Hz, H-6), 6.61 (1H, d, J = 3.0 Hz, H-1́ ), 6.48 (1H, s, 2´-OH), 5.30 (1H, dd, 
J = 2.2 and 12.2 Hz, H-5 á), 5.26 (1H, dd, J = 2.2 and 12.2 Hz, H-5´b), 5.15 (1H, s, 3´-OH), 4.85 (1H, dd, 
J = 2.2 and 5.6 Hz, H-4´), 4.50 (2H, s, -NH2), 4.25 (1H, d, J = 3.2 Hz, H-2´), 4.01 (1H, dd, J = 3.6 and 
5.8 Hz, H-3´), 3.91 (1H, d, J = 7.2 Hz, H-5). MS [M+1]+ 486.08. 
Anal Calcd. for C28H27O5N3: % C, 69.28, H, 5.56; % found: C, 69.27, H, 5.53. 
General procedure for the direct 2′,3′-di-O-acylation  
of 5´-O-(triphenylmethyl)cytidine derivatives (9–15) 
The triphenylmethyl derivative (8, 60 mg, 0.124 mmol) was dissolved in dry DMF (3 ml), and the 
solution was cooled to 0 °C when hexanoyl chloride (0.067 ml, 4 molar eq.) was added. The mixture 
was stirred at 0 °C for 6 h and at room temperature overnight. The conventional work-up procedure and 
subsequent chromatographic purification with the CHCl3–CH3OH (1:24) eluant led to the formation of 
2’,3’-di-O-hexanoyl derivative (9) (157 mg).
2 ,́3´-Di-O-hexanoyl-5´-O-(triphenylmethyl)cytidine (9): Yield 81.5% as crystalline solid, M.P. 
100–102 °C, Rf = 0.52 (CHCl3/CH3OH = 22/1, v/v). FTIR: νmax 1710 (-CO), 3503 cm-1 (-NH). 1H-NMR 
(400 MHz, CDCl3): δH 9.08 (1H, s, -NH), 7.32 (6H, m, Ar-H), 7.28 (9H, m, Ar-H), 7.21 (1H, d, J = 7.6 Hz, 
H-6), 6.51 (1H, d, J = 3.2 Hz, H-1́ ), 5.47 (1H, m, H-2´), 4.88 (1H, dd, J = 3.2 and 5.4 Hz, H-3´), 4.61 
(1H, dd, J = 2.2 and 12.2 Hz, H-5 á), 4.54 (2H, s, -NH2), 4.48 (1H, dd, J = 2.2 and 12.2 Hz, H-5´b), 4.35 
(1H, dd, J = 2.2 and 5.4 Hz, H-4´), 3.81 (1H, d, J = 7.1 Hz, H-5), 2.31 {4H, m, 2×CH3(CH2)3CH2CO-}, 
1.62 {4H, m, 2×CH3(CH2)2CH2CH2CO-}, 1.26 {8H, m, 2×CH3(CH2)2CH2CH2CO-}, 0.88 {6H, m, 
2×CH3(CH2)4CO-}. MS [M+1]+ 682.05. 
Anal Calcd. for C40H47O7N3: % C, 70.40, H, 6.90; % found: C, 70.42, H, 6.91. 
A similar reaction and purification method were employed to synthesize compounds (10) (164 mg), 
(11) (152 mg), (12) (109.5 mg), (13) (100.4 mg), (14) (132 mg), and (15) (111 mg). 
2 ,́ 3´-Di-O-heptanoyl-5´-O-(triphenylmethyl)cytidine (10): Yield 78.9% as crystalline 
solid, M.P. 98–99 °C (CHCl3–C6H14), Rf = 0.50 (CHCl3/CH3OH = 24/1, v/v). FTIR: νmax 1715 (-CO), 
3506 cm-1 (-NH). 1H-NMR (400 MHz, CDCl3): δH 9.03 (1H, s, -NH), 7.30 (6H, m, Ar-H), 7.28 (9H, 
m, Ar-H), 7.20 (1H, d, J = 7.4 Hz, H-6), 6.44 (1H, d, J = 3.2 Hz, H-1́ ), 5.50 (1H, d, J = 3.2 Hz, H-2´), 
5.24 (1H, dd, J = 3.2 and 5.4 Hz, H-3´), 5.06 (1H, dd, J = 2.2 and 12.2 Hz, H-5 á), 4.65 (2H, s, -NH2), 
4.02 (1H, dd, J = 2.1 and 12.1 Hz, H-5´b), 3.95 (1H, dd, J = 2.2 and 5.3 Hz, H-4´), 3.80 (1H, m, 
H-5), 2.41 {4H, m, 2×CH3(CH2)4CH2CO-}, 1.62 {4H, m, 2×CH3(CH2)3CH2CH2CO-}, 1.35 {12H, m, 
2×CH3(CH2)3CH2CH2CO-}, 0.91 {6H, m, 2×CH3(CH2)5CO-}. MS [M+1]+ 710.14. 
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Anal Calcd. for C42H53O7N3: % C, 71.00, H, 7.10; % found: C, 71.02, H, 7.09. 
2 ,́3´-Di-O-lauroyl-5´-O-(triphenylmethyl)cytidine (11): Yield 93.2% as a white crystalline 
solid, M.P. 107–109 °C (CHCl3–C6H14), Rf = 0.50 (CHCl3/CH3OH = 23/1, v/v). FTIR: νmax 1735 (-CO), 
3500 cm-1 (-NH). 1H-NMR (400 MHz, CDCl3): δH 9.00 (1H, s, -NH), 7.36 (6H, m, Ar-H), 7.31 (9H, m, 
Ar-H), 7.28 (1H, d, J = 7.3 Hz, H-6), 6.47 (1H, d, J = 3.3 Hz, H-1́ ), 5.57 (1H, d, J = 3.2 Hz, H-2´), 5.27 
(1H, dd, J = 3.2 and 5.4 Hz, H-3´), 5.11 (1H, dd, J = 2.1 and 12.1 Hz, H-5 á), 4.58 (2H, s, -NH2), 4.11 
(1H, dd, J = 2.2 and 12.2 Hz, H-5´b), 3.99 (1H, dd, J = 2.1 and 5.2 Hz, H-4´), 3.85 (1H, d, J = 7.1 Hz, 
H-5), 2.37 {4H, m, 2×CH3(CH2)9CH2CO-}, 1.68 {4H, m, 2×CH3(CH2)8CH2CH2CO-}, 1.29 {32H, m, 
2×CH3(CH2)8CH2CH2CO-}, 0.89 {6H, m, 2×CH3(CH2)10CO-}. MS [M+1]+ 850.23.
Anal Calcd. for C52H71O7N3: % C, 73.50, H, 8.36; % found: C, 73.49, H, 8.35. 
2 ,́3´-Di-O-myristoyl-5´-O-(triphenylmethyl)cytidine (12): Yield 88.75.3% as a crystalline 
solid, M.P. 96–98 °C (CHCl3–C6H14), Rf = 0.51 (CHCl3/CH3OH = 24/1, v/v). FTIR: νmax 1726 (-CO), 
3470 cm-1 (-NH). 1H-NMR (400 MHz, CDCl3): δH 9.09 (1H, s, -NH), 7.38 (6H, m, Ar-H), 7.33 (9H, m, 
Ar-H), 7.29 (1H, d, J = 7.4 Hz, H-6), 6.40 (1H, d, J = 3.2 Hz, H-1́ ), 5.51 (1H, d, J = 3.2 Hz, H-2´), 5.20 
(1H, dd, J = 3.1 and 5.2 Hz, H-3´), 5.01 (1H, dd, J = 2.1 and 12.1 Hz, H-5 á), 4.59 (2H, s, -NH2), 4.10 
(1H, dd, J = 2.1 and 12.1 Hz, H-5´b), 3.89 (1H, dd, J = 2.1 and 5.2 Hz, H-4´), 3.87 (1H, d, J = 7.1 Hz, 
H-5), 2.38 {4H, m, 2×CH3(CH2)11CH2CO-}, 1.68 {4H, m, 2×CH3(CH2)10CH2CH2CO-}, 1.29 {40H, m, 
2×CH3(CH2)10CH2CH2CO-}, 0.95 {6H, m, 2×CH3(CH2)12CO-}. MS [M+1]+ 906.04. 
Anal Calcd. for C56H79O7N3: % C, 74.25, H, 8.73; % found: C, 74.27, H, 8.74. 
2 ,́3´-Di-O-pivaloyl-5´-O-(triphenylmethyl)cytidine (13): Yield 91.4% as crystalline solid, M.P. 
96–97 °C (CHCl3–C6H14), Rf = 0.55 (CHCl3/CH3OH = 24/1, v/v). FTIR: νmax 1718 (-CO), 3501 cm-1 
(-NH). 1H-NMR (400 MHz, CDCl3): δH 9.04 (1H, s, -NH), 7.33 (6H, m, Ar-H), 7.30 (9H, m, Ar-H), 
7.20 (1H, d, J = 7.5 Hz, H-6), 6.36 (1H, d, J = 3.1 Hz, H-1́ ), 5.50 (1H, d, J = 3.1 Hz, H-2´), 5.10 (1H, dd, 
J = 3.2 and 5.2 Hz, H-3´), 5.00 (1H, dd, J = 2.2 and 12.2 Hz, H-5 á), 4.89 (2H, s, -NH2), 4.11 (1H, dd, 
J = 2.2 and 12.1 Hz, H-5´b), 3.92 (1H, dd, J = 2.2 and 5.4 Hz, H-4´), 3.90 (1H, d, J = 7.1 Hz, H-5), 1.26 
{18H, s, 2×(CH3)3CCO-}. MS [M+1]+ 654.01. 
Anal Calcd. for C38H43O7N3: % C, 69.83, H, 6.58; % found: C, 69.84, H, 6.60. 
2 ,́3´-Di-O-(4-chlorobenzoyl)-5´-O-(triphenylmethyl) cytidine (14): Yield 78.3% as a white 
crystalline solid, M.P. 99–101 °C (CHCl3–C6H14), Rf = 0.52 (CHCl3/CH3OH = 22/1, v/v). FTIR: νmax 
1711 (-CO), 3505 cm-1 (-NH). 1H-NMR (400 MHz, CDCl3): δH 9.01 (1H, s, -NH), 7.98 (4H, m, Ar-H), 
7.58 (4H, m, Ar-H), 7.32 (6H, m, Ar-H), 7.28 (9H, m, Ar-H), 7.21 (1H, d, J = 7.5 Hz, H-6), 6.44 (1H, d, 
J = 3.1 Hz, H-1́ ), 5.58 (1H, d, J = 3.2 Hz, H-2´), 5.12 (1H, dd, J = 3.2 and 5.2 Hz, H-3´), 5.02 (1H, dd, 
J = 2.2 and 12.2 Hz, H-5 á), 4.60 (2H, s, -NH2), 4.10 (1H, dd, J = 2.1 and 12.1 Hz, H-5´b), 4.00 (1H, dd, 
J = 2.2 and 5.4 Hz, H-4´), 3.92 (1H, d, J = 7.1 Hz, H-5). MS [M+1]+ 763.22. 
Anal Calcd. for C42H33O7N3Cl2: % C, 66.14, H, 4.33; % found: C, 66.12, H, 4.32. 
2´,3´-Di-O-cinnamoyl-5´-O-(triphenylmethyl)cytidine (15): Yield 88.5% white crystalline 
solid, M.P. 102–104 °C (CHCl3–C6H14), R f = 0.50 (CHCl3/CH3OH = 22/1, v/v). FTIR: νmax 1678 
(-CO), 3492 cm-1 (-NH). 1H-NMR (400 MHz, CDCl3): δH 9.02 (1H, s, -NH), 7.85 (4H, m, Ar-H), 
7.40 (6H, m, Ar-H), 7.60, 7.57 (2×1H, 2×d, J = 16.1 Hz, 2×PhCH=CHCO-), 7.36 (6H, m, Ar-H), 7.31 
(9H, m, Ar-H), 7.28 (1H, d, J = 7.4 Hz, H-6), 6.45 (1H, d, J = 3.2 Hz, H-1´), 6.48, 6.42 (2×1H, 2×d, 
J = 16.1 Hz, 2×PhCH=CHCO-), 5.68 (1H, d, J = 3.3 Hz, H-2´), 5.34 (1H, dd, J = 3.3 and 5.3 Hz, 
H-3´), 4.97 (1H, dd, J = 2.2 and 12.2 Hz, H-5´a), 4.61 (2H, s, -NH2), 4.31 (1H, dd, J = 2.2 and 
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12.2 Hz, H-5´b), 4.15 (1H, dd, J = 2.2 and 5.4 Hz, H-4´), 3.62 (1H, d, J = 7.1 Hz, H-5). MS [M+1]+ 
743.30. 
Anal Calcd. for C46H36O7N3: % C, 74.39, H, 4.85; % found: C, 74.41, H, 4.84. 
X-ray powder diffraction
X-ray powder diffraction was performed using Rigaku Dmax2200PC diffractometer (Rigaku 
Corporation, Tokyo, Japan) and Cu Kα-radiation [22]. The X-ray intensity was measured in the range 
of 5° ≤ 2θ ≤ 90° with a scan speed of 2°·min−1. The peak position of the 002 coke peak was measured. 
By using Bragg’s law, the interlayer d-spacing was calculated. The improved Langford method was 
employed to calculate the stacking disorder degree, P.
Results and discussion
Chemistry 
In this study, regioselective decanoylation (Fig. 2 and 3) and triphenylmethylation (Fig. 4 
and 5) of cytidine (1) were performed using the direct method. The resulting decanoylation and 
triphenylmethylation products were converted into numerous analogs by employing various acylating 
agents. 
Characterization and selective decanoyl of cytidine 
Cytidine 1 was initially converted into the 5´-O-decanoylcytidine derivative 2 through treatment 
with dry pyridine, and this product after the reaction with decanoyl chloride, followed by solvent 
removal and silica gel column chromatographic purification, produced 5/-O-decanoyl derivative (2) 
with 83.8% yield as needles and m.p. of 85–87 °C). The FTIR spectrum of compound 2 showed the 
following absorption bands: 1731, 1714 cm−1 (due to –CO), 3420 cm−1 (due to –OH), and 3550 cm−1 
(due to –NH) stretching. In its 1H-NMR spectrum, two two-proton multiplets observed at δ 2.38 
{CH3(CH2)7CH2CO–} and δ 1.59 {CH3(CH2)6CH2CH2CO–}, a twelve-proton multiplet appearing at 
δ 1.32 {CH3(CH2)6(CH2)2CO–}, and a three-proton multiplet seen at δ 0.85 {CH3(CH2)8CO–} were 
caused by the presence of one decanoyl group in the molecule. The downfield shift of C-5/ proton 
to δ 6.01 (as dd, J = 2.4 and 12.3 Hz, H-5 á) and to δ 5.56 (as dd, J = 2.4 and 12.3 Hz, H-5´b) from 
their general values [23] in the precursor compound (1) and the resonances of other protons in their 
anticipated positions indicated the presence of the decanoyl group at position 5/. The formation of 
5´-O-decanoylcytidine (2) might be caused by the high reactivity of the sterically less hindered 
Fig. 2. Reagents and conditions: (a) dry C6H5N, −5 °C, 6 to 7 h; 2 = decanoyl derivative
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Fig. 3. (b) dry pyridine, 0 °C to room temperature, DMAP, stir for 6–8 h, R1 = different acyl halides (3–7)
Fig. 4. Reagents and conditions: (c) dry C6H5N, 0–5°C, 6 h; 8 = triphenylmethyl derivative
primary hydroxyl group of the ribose moiety of cytidine (1). Mass spectrometry provided a molecular 
ion peak at m/z [M+1]+ 398.10, which corresponded to the aforementioned molecular formula. From 
the complete analysis of FTIR, 1H-NMR, and elemental data, the structure of this compound was 
assigned as 5´-O-decanoylcytidine (2).
Furthermore, the structure of compound (2) was confirmed through the preparation of its 
octanoyl derivatives (3) (77.6%) as the crystalline solid with the m.p. of 89–91 °C. In its 1H-NMR 
spectrum, two four-proton multiplets appearing at δ 2.37 {2 × CH3(CH2)5CH2CO–} and 1.64 {2 × 
CH3(CH2)4CH2CH2CO–}, sixteen-proton multiplet observed at δ 1.29 {2×CH3(CH2)4(CH2)2CO–}, and 
six-proton multiplet obtained at δ 0.89 {2 × CH3(CH2)6CO–} were caused by the presence of two 
octanoyl groups in the molecule. The downfield shift of H-2/ and H-3/ protons to δ 5.45 and δ 4.82 from 
their precursor values (2) [24] indicated the attachment of two octanoyl groups at positions 2/ and 3/. 
The structure of octanoyl derivatives (3) was confirmed as 5´-O-decanoyl-2 ,́3´-di-O-octanoylcytidine 
(3)through the complete analysis of their FTIR, 1H-NMR, and elemental data.
Through the palmitoylation of compound (2) by using palmitoyl chloride as acylating agent in 
C5H5N at room temperature, we isolated compound 4 in good yield. The following resonance peaks 
ascertained the presence of two palmitoyl groups in the molecule: δ 2.36 {4H, m, 2 × CH3(CH2)13CH2CO–}, 
δ 1.27 {52H, m, 2 × CH3(CH2)13CH2CO–}, and δ 0.91 {6H, m, 2 × CH3(CH2)14CO–}. The introduction 
of palmitoyl groups at position 2/ and 3/ was indicated by appearance of H-2/ and H-3/ resonance peaks 
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at δ 5.48 (as m) and δ 4.86 (as dd, J = 3.5 and 5.6 Hz), which were deshielded considerably from their 
precursor diol (2) peaks. The decanoyl derivative 2 was further transformed easily into the 2 ,́3´-di-O-
stearoyate 5, 2 ,́3´-di-O-(triphenylmethyloate) 6, and 2 ,́3´-(4-tert-butylbenzoate) 7.
Characterization and selective triphenylmethylation of cytidine 
Cytidine (1) was then transformed into the 5´-O-(triphenylmethyl)cytidine derivative 8 through a 
treatment with a unimolecular amount of triphenylmethyl chloride in anhydrous pyridine at −5 °C. The 
conventional work-up procedure, followed by solvent removal and silica gel column chromatographic 
purification, produced high yields of the triphenylmethyl derivative (8) as the crystalline solid. In its 
1H-NMR spectrum, two characteristic six-proton multiplets appearing at δ 7.35 (Ar–H) and nine-
proton multiplets observed at δ 7.30 (Ar–H) were caused by three phenyl protons of the triphenylmethyl 
group in the molecule. The downfield shift of C-5/ proton to δ 5.30 (as dd, J = 2.2 and 12.2 Hz, H-5 á) 
and to 5.26 (as dd, J = 2.2 and 12.2 Hz, H-5´b) from their usual values (~4.00 ppm) in the precursor 
compound (1) and the resonances of other protons at their anticipated positions showed the presence of 
the triphenylmethyl group at position 5/. This finding is in accordance with the mechanism proposed 
by Kawsar et al. [25] based on similar nucleoside derivatives.
The preparation and identification of hexanoyl derivative 9 further supported the 
structure of compound 8. The 1H-NMR spectra exhibited two four-proton multiplets at δ 2.31 
{2 × CH3(CH2)3CH2CO–} and at δ 1.62 {2 × CH3(CH2)2CH2CH2CO–}, eight-proton multiplet at δ 1.26 
{2 × CH3(CH2)2CH2CH2CO–}, and six-proton multiplet at δ 0.88 {2 × CH3(CH2)4CO–}, which showed 
the attachment of two hexanoyl groups indicating the formation of 2 ,́3´-di-O-hexanoate 9. 
Compound 8 was then converted into heptanoyl derivative 10 by using similar procedures, and 
a high yield of heptanoate 10 was isolated as needles, (m.p. 98–99 °C). From the complete analysis of 
the FTIR, 1H-NMR, and elemental data, the structure of this compound was confirmed as 2 ,́3´-di-O-
heptanoyl -5´-O-(triphenylmethyl)cytidine (10). Similarly, compound 8 was converted into numerous 
acylated derivatives (11–15) to obtain newer compounds for antimicrobial evaluation studies. The 
structures of these derivatives were ascertained through the complete interpretation of their FTIR and 
1H-NMR spectra. 
Fig. 5. Reagents and conditions: (d) anhydr. pyridine, 0 °C to room temperature, DMAP, stir for 6 to 7 h, 
R2 = several acyl halides (9–15)
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Thus, cytidine (1) acylation by applying the direct method was unique, and the reaction provided 
a single mono-substituted product in reasonably high yields. These newly synthesized products may 
be used as important precursors to modify cytidine molecules at different positions. All the prepared 
products were employed as test compounds for evaluating their antimicrobial and anticancer activities 
and for computational investigations. 
XRD measurements
XRD is mainly performed for quantitatively identifying crystalline compounds, whereas single 
crystal XRD is conducted for structure determination. If h, k, and l represent the miller indices, the 
rules of the determination of crystal lattice type are as follows (Table 1).
The XRD patterns of the pure compounds synthesized under the optimized conditions were 
obtained in the 2θ range of (0°–50°). The peaks observed at 2θ of 19.653 and 21.506 (h,k,l:112 & 
220), 6.010 and 21.472 (h,k,l:320 & 100), 8.386 and 20.212 (h,k,l:100 & 100), and 7.427 and 12.360 
(h,k,l:100 & 111) corresponded to compounds 4, 5, 13, and 15, respectively. These peaks indicated 
the formation of typical phases of compounds 4, 5, 13, and 15. According to the phase analysis, the 
compounds synthesized using this method have high purity, and no impurities were detected in the 
XRD pattern. Moreover, compounds 4, 5, 13, and 15 show many lines with high intensity in their XRD 
patterns, which indicated that all the compounds are highly crystalline (Fig. 6). By applying the rules 
(Table 1) of the determination of the lattice type, we assigned the lattice structures to the synthesized 
Table 1. Rules of the determination of crystal lattice type
Lattice type Rules for reflection to be observed
Primitive, P None
Body centered, I hkl; h+k+l= 2n
Face centered, F hkl; h,k,l either all odd or all even
Side centered, C hkl; h+k= 2n
Rhombohedral hkl; -h+k+l= 3n or h-k+l= 3n
Fig. 6. XRD pattern of 2′,3′-di-O-pivaloyl-5′-O-(triphenylmethyl)cytidine (13)
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compounds. Compound 4 satisfied the rule, h + k + l = 2n and was assigned the body centered lattice, 
while compounds 5, 13, and 15 were assigned primitive, for which no rule was provided.
Conclusion
In conclusion, an efficient method was proposed for synthesizing cytidine analogs. Moreover, 
acylation reactions are highly promising because considerably high yields of a single mono-substituted 
product were isolated through all the reactions. XRD pattern showed that the compounds 4, 5, 13 and 
15 exhibited many lines with high intensity and suggested these compounds are well crystalline.
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